Tumor and its microenvironment: A synergistic interplay

Seminars in Cancer Biology

Volumn 23, Issue 6 PB, 2013, Pages 522-532

  Catalano, Veronica ^a   Turdo, Alice ^a   Di Franco, Simone ^a   Dieli, Francesco ^b   Todaro, Matilde ^a   Stassi, Giorgio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Angiogenesis; CSCs; Hypoxia; ROS; Tumor microenvironment

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; AFLIBERCEPT; ANTHRACYCLINE; BEVACIZUMAB; BORTEZOMIB; CISPLATIN; DIGOXIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR; IRINOTECAN; OXALIPLATIN; REACTIVE OXYGEN METABOLITE; REGORAFENIB; SALAZOSULFAPYRIDINE; TOPOTECAN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER STEM CELL; CELL INTERACTION; CELL MOTILITY; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; DRUG MECHANISM; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; HYPOXIA; MANTLE CELL LYMPHOMA; METASTASIS; METASTATIC COLORECTAL CANCER; MULTIPLE MYELOMA; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROSTATE TUMOR; PROTEIN PROTEIN INTERACTION; REVIEW; STEM CELL NICHE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANGIOGENESIS; CAFS; CAMS; CANCER STEM CELLS; CANCER-ASSOCIATED FIBROBLASTS; CANCER-ASSOCIATED MACROPHAGES; COLORECTAL CANCER; CRC; CSCS; ECM; EMT; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GSH; HIF; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR; MATRIX METALLOPROTEINASE; MMPS; REACTIVE OXYGEN SPECIES; REDUCED GLUTATHIONE; ROS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; ANOXIA; CELL MOVEMENT; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84887613510     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.08.007     Document Type: Review

References (119)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics CA. Cancer J Clin 2011, 61:69-90.
2. Janne P.A., Mayer R.J. Chemoprevention of colorectal cancer. N Engl J Med 2000, 342:1960-1968.
3. Dieter S.M., Ball C.R., Hoffmann C.M., Nowrouzi A., Herbst F., Zavidij O., et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
4. Maugeri-Sacca M., Vigneri P., De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011, 17:4942-4947.
5. Sun Y., Nelson P.S. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012, 18:4019-4025.
6. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
7. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
8. Galiatsatos P., Foulkes W.D. Familial adenomatous polyposis. Am J Gastroenterol 2006, 101:385-398.
9. Fearnhead N.S., Britton M.P., Bodmer W.F. The ABC of APC. Hum Mol Genet 2001, 10:721-733.
10. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
11. De Sousa E.M.F., Wang X., Jansen M., Fessler E., Trinh A., de Rooij L.P., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013, 19:614-618.
12. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
13. Paget S. The distribution of secondary growths in cancer of the breast 1889. Cancer Metastasis Rev 1989, 8:98-101.
14. Adegboyega P.A., Mifflin R.C., DiMari J.F., Saada J.I., Powell D.W. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med 2002, 126:829-836.
15. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., West A.B. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999, 277:C183-C201.
16. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010, 12:468-476.
17. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
18. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999, 96:5522-5527.
19. Tetsu O., McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426.
20. Gregorieff A., Pinto D., Begthel H., Destree O., Kielman M., Clevers H. Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology 2005, 129:626-638.
21. He X.C., Yin T., Grindley J.C., Tian Q., Sato T., Tao W.A., et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007, 39:189-198.
22. Persad S., Troussard A.A., McPhee T.R., Mulholland D.J., Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 2001, 153:1161-1174.
23. Rider C.C., Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J 2010, 429:1-12.
24. van Es J.H., de Geest N., van de Born M., Clevers H., Hassan B.A. Intestinal stem cells lacking the Math1 tumour suppressor are refractory to Notch inhibitors. Nat Commun 2010, 1:18.
25. Hegde G.V., Munger C.M., Emanuel K., Joshi A.D., Greiner T.C., Weisenburger D.D., et al. Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma. Mol Cancer Ther 2008, 7:1450-1460.
26. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
27. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
28. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981.
29. Le N.H., Franken P., Fodde R. Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br J Cancer 2008, 98:1886-1893.
30. Gulhati P., Bowen K.A., Liu J., Stevens P.D., Rychahou P.G., Chen M., et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011, 71:3246-3256.
31. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007, 98:1512-1520.
32. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
33. Friedl P., Wolf K. Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev 2009, 28:129-135.
34. Lammermann T., Sixt M. Mechanical modes of 'amoeboid' cell migration. Curr Opin Cell Biol 2009, 21:636-644.
35. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003, 160:267-277.
36. Guilluy C., Garcia-Mata R., Burridge K. Rho protein crosstalk: another social network. Trends Cell Biol 2011, 21:718-726.
37. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E., et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001, 12:27-36.
38. Chan A.Y., Coniglio S.J., Chuang Y.Y., Michaelson D., Knaus U.G., Philips M.R., et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 2005, 24:7821-7829.
39. Makrodouli E., Oikonomou E., Koc M., Andera L., Sasazuki T., Shirasawa S., et al. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer 2011, 10:118.
40. Pani G., Galeotti T., Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 2010, 29:351-378.
41. Fiaschi T., Marini A., Giannoni E., Taddei M.L., Gandellini P., De Donatis A., et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 2012, 72:5130-5140.
42. Giannoni E., Parri M., Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal 2012, 16:1248-1263.
43. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
44. Dong R., Wang Q., He X.L., Chu Y.K., Lu J.G., Ma Q.J. Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-alpha-induced epithelial-mesenchymal transition of MCF-7 cells. Braz J Med Biol Res 2007, 40:1071-1078.
45. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
46. Laberge R.M., Awad P., Campisi J., Desprez P.Y. Epithelial-mesenchymal transition induced by senescent fibroblasts. Cancer Microenviron 2012, 5:39-44.
47. Klimova T., Chandel N.S. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 2008, 15:660-666.
48. Rhyu D.Y., Yang Y., Ha H., Lee G.T., Song J.S., Uh S.T., et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005, 16:667-675.
49. Zhang K.H., Tian H.Y., Gao X., Lei W.W., Hu Y., Wang D.M., et al. Ferritin heavy chain-mediated iron homeostasis and subsequent increased reactive oxygen species production are essential for epithelial-mesenchymal transition. Cancer Res 2009, 69:5340-5348.
50. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005, 10:1881-1896.
51. Tsuji Y. JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress. Oncogene 2005, 24:7567-7578.
52. Ishimoto T., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19:387-400.
53. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002, 16:3074-3086.
54. Misra S., Hascall V.C., De Giovanni C., Markwald R.R., Ghatak S. Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem 2009, 284:12432-12446.
55. Jung T., Gross W., Zoller M. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 2011, 286:15862-15874.
56. Qu Y., Wang J., Ray P.S., Guo H., Huang J., Shin-Sim M., et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-kappaB signaling. J Clin Invest 2011, 121:212-225.
57. Yae T., Tsuchihashi K., Ishimoto T., Motohara T., Yoshikawa M., Yoshida G.J., et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012, 3:883.
58. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010, 16:5928-5935.
59. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia and cancer. J Mol Med (Berl) 2007, 85:1301-1307.
60. Zeng M., Kikuchi H., Pino M.S., Chung D.C. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One 2010, 5:e10966.
61. Heddleston J.M., Li Z., McLendon R.E., Hjelmeland A.B., Rich J.N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284.
62. Xue X., Taylor M., Anderson E., Hao C., Qu A., Greenson J.K., et al. Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res 2012, 72:2285-2293.
63. Cannito S., Novo E., Compagnone A., Valfre di Bonzo L., Busletta C., Zamara E., et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008, 29:2267-2278.
64. Yang M.H., Wu M.Z., Chiou S.H., Chen P.M., Chang S.Y., Liu C.J., et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008, 10:295-305.
65. Higgins D.F., Kimura K., Bernhardt W.M., Shrimanker N., Akai Y., Hohenstein B., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007, 117:3810-3820.
66. Peinado H., Del Carmen Iglesias-de la Cruz M., Olmeda D., Csiszar K., Fong K.S., Vega S., et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J 2005, 24:3446-3458.
67. Krishnamachary B., Berg-Dixon S., Kelly B., Agani F., Feldser D., Ferreira G., et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003, 63:1138-1143.
68. Hongo K., Tsuno N.H., Kawai K., Sasaki K., Kaneko M., Hiyoshi M., et al. Hypoxia enhances colon cancer migration and invasion through promotion of epithelial-mesenchymal transition. J Surg Res 2013, 182:75-84.
69. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
70. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
71. Funasaka T., Raz A. The role of autocrine motility factor in tumor and tumor microenvironment. Cancer Metastasis Rev 2007, 26:725-735.
72. Loayza-Puch F., Yoshida Y., Matsuzaki T., Takahashi C., Kitayama H., Noda M. Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs. Oncogene 2010, 29:2638-2648.
73. Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
74. Kucia M., Ratajczak J., Ratajczak M.Z. Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells. Biol Cell 2005, 97:133-146.
75. Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008, 27:253-261.
76. Gupta G.P., Perk J., Acharyya S., de Candia P., Mittal V., Todorova-Manova K., et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 2007, 104:19506-19511.
77. Kakonen S.M., Selander K.S., Chirgwin J.M., Yin J.J., Burns S., Rankin W.A., et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002, 277:24571-24578.
78. Batlle R., Alba-Castellon L., Loubat-Casanovas J., Armenteros E., Franci C., Stanisavljevic J., et al. Snail1 controls TGF-beta responsiveness and differentiation of mesenchymal stem cells. Oncogene 2012, 32:3381-3389.
79. Hillen F., Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007, 26:489-502.
80. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006, 66:7843-7848.
81. Folkins C., Shaked Y., Man S., Tang T., Lee C.R., Zhu Z., et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009, 69:7243-7251.
82. Lu J., Ye X., Fan F., Xia L., Bhattacharya R., Bellister S., et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 2013, 23:171-185.
83. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
84. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000, 97:14608-14613.
85. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
86. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
87. Cheng L., Huang Z., Zhou W., Wu Q., Donnola S., Liu J.K., et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013, 153:139-152.
88. Lin S.P., Lee Y.T., Yang S.H., Miller S.A., Chiou S.H., Hung M.C., et al. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett 2013, 328:226-234.
89. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 2012, 109:2784-2789.
90. Wong M.P., Cheung N., Yuen S.T., Leung S.Y., Chung L.P. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999, 81:845-850.
91. Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W., et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005, 24:2647-2653.
92. Waldner M.J., Wirtz S., Jefremow A., Warntjen M., Neufert C., Atreya R., et al. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med 2010, 207:2855-2868.
93. Yao X., Ping Y., Liu Y., Chen K., Yoshimura T., Liu M., et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS One 2013, 8:e57188.
94. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995, 92:3566-3570.
95. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198.
96. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580.
97. Mizukami Y., Fujiki K., Duerr E.M., Gala M., Jo W.S., Zhang X., et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006, 281:13957-13963.
98. Wang D., Dubois R.N. Eicosanoids and cancer. Nat Rev Cancer 2010, 10:181-193.
99. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006, 203:941-951.
100. Saharinen P., Eklund L., Pulkki K., Bono P., Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011, 17:347-362.
101. McLellan E.A., Owen R.A., Stepniewska K.A., Sheffield J.P., Lemoine N.R. High frequency of K-ras mutations in sporadic colorectal adenomas. Gut 1993, 34:392-396.
102. Li J., Mizukami Y., Zhang X., Jo W.S., Chung D.C. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology 2005, 128:1907-1918.
103. Zhang X., Gaspard J.P., Chung D.C. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001, 61:6050-6054.
104. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
105. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
106. Sawada J., Urakami T., Li F., Urakami A., Zhu W., Fukuda M., et al. Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell 2012, 22:235-249.
107. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
108. Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., Petersen G.M., et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001, 28:184-187.
109. He X.C., Zhang J., Tong W.G., Tawfik O., Ross J., Scoville D.H., et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet 2004, 36:1117-1121.
110. Shao E.S., Lin L., Yao Y., Bostrom K.I. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 2009, 114:2197-2206.
111. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
112. Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 2012, 5:63.
113. Saltz L.B., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
114. Lu K.V., Chang J.P., Parachoniak C.A., Pandika M.M., Aghi M.K., Meyronet D., et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22:21-35.
115. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6:33-43.
116. Kaluz S., Kaluzova M., Stanbridge E.J. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol 2006, 26:5895-5907.
117. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009, 106:2353-2358.
118. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002, 277:29936-29944.
119. Onnis B., Rapisarda A., Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009, 13:2780-2786.